What is Zonisamide
Zonisamide is a broad-spectrum antiepileptic drug (sulfonamide derivative) approved as adjunctive therapy for partial seizures in adults, with multiple mechanisms of action including sodium channel blockade, T-type calcium channel inhibition, and carbonic anhydrase inhibition. 1
Mechanism of Action
Zonisamide works through several distinct pathways 1:
- Blocks voltage-dependent sodium channels, stabilizing neuronal membranes and suppressing hypersynchronization
- Reduces T-type calcium currents, preventing transient inward calcium flow
- Carbonic anhydrase inhibition (though the contribution to antiseizure effects is unclear)
- Facilitates dopaminergic and serotonergic neurotransmission
- Does NOT appear to potentiate GABA activity, despite binding to GABA/benzodiazepine receptor complexes
The precise mechanism by which these actions produce antiseizure effects remains unknown 1.
FDA-Approved Indication
Zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy 1. While used off-label for other seizure types and conditions, this remains the only FDA-approved indication in the United States.
Efficacy Data
Based on Class I evidence from two pivotal trials 2:
- 100-200 mg/day: 25% responder rate (≥50% seizure reduction)
- 400 mg/day: 43% responder rate
- 20 mg/kg dose: 30% responder rate vs. 9.4% for placebo
The American Academy of Neurology guidelines confirm zonisamide is appropriate for adjunctive treatment of refractory partial seizures in adults 2.
Dosing
Pharmacokinetic profile 1:
- Half-life: ~60 hours, allowing once or twice-daily dosing
- Time to peak concentration: 2-6 hours (4-6 hours with food)
- Steady state: Achieved within 14 days
- Protein binding: ~40%
- Volume of distribution: 1.45 L/kg
- Concentrates 8-fold in red blood cells compared to plasma
Typical dosing range: 300-600 mg/day in clinical trials 2, though doses of 100-500 mg/day have been studied 3, 4.
Adverse Effects
Most common (Class I evidence) 2:
- Fatigue
- Dizziness
- Somnolence
- Anorexia
- Abnormal thinking
Additional adverse events from trials:
- Renal calculi (important consideration given carbonic anhydrase inhibition)
- Rhinitis
- Rash
- Paranoia
- Depression
- Metabolic acidosis (due to carbonic anhydrase inhibition) 1
Discontinuation rate: 10% in clinical trials, similar to placebo 2.
Contraindications
Zonisamide is contraindicated in patients with hypersensitivity to sulfonamides or zonisamide 1. This is critical—always screen for sulfa allergy before prescribing.
Key Clinical Advantages
- Long half-life enables once-daily dosing, improving adherence
- Low potential for drug interactions, including with oral contraceptives 3
- No hepatic enzyme induction 4
- Dose-proportional pharmacokinetics in the 200-400 mg range 1
- Broad spectrum activity demonstrated in multiple seizure types beyond FDA indication 3, 5, 6
Important Caveats
Metabolic acidosis warning: As a carbonic anhydrase inhibitor, zonisamide can cause metabolic acidosis—monitor bicarbonate levels, especially in patients with renal disease or on ketogenic diets 1.
Pediatric use: While no Class I evidence exists for pediatric partial seizures 2, the drug has been studied in children for other indications. A case of hypohidrosis in a child has been reported 2.
Titration: Standard titration takes several weeks to reach therapeutic levels, though one study suggests loading doses of 600-900 mg over 6-12 hours may be safe and achieve therapeutic levels faster 7.